Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/1b Single Arm Safety Lead in Study of Leronlimab (CCR5 Blockade) With Hepatic Arterial Infusion Pump Therapy Delivering Floxuridine (FUDR) and Concurrent Systemic Therapy in Colorectal Cancer Liver Metastases Patients (CHAMP)

NCT07842965 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT07842965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07842965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/1b Single Arm Safety Lead in Study of Leronlimab (CCR5 Blockade) With Hepatic Arterial Infusion Pump Therapy Delivering Floxuridine (FUDR) and Concurrent Systemic Therapy in Colorectal Cancer Liver Metastases Patients (CHAMP)
Lead sponsor
City of Hope Medical Center
Phase
Phase 1
Overall status
Not yet recruiting
Start date
May 6, 2027
Completion date
February 2, 2028
Enrollment
36 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic colorectal carcinoma, metastatic malignant neoplasm in the liver, stage iv colorectal cancer ajcc v8